NICE Issues Another No to Merck’s Keytruda for Advanced Bladder Cancer

The UK’s National Institute for Health and Care Excellence (NICE) has decided it will not fund Keytruda (pembrolizumab), Merck’s second-line advanced bladder cancer drug.
Source: Drug Industry Daily